AQP4 and blood disease: It is also used in adults and children weighing at least 5 kg to treat a blood disease called atypical hemolytic uremia (aHUS, approved in 2011), as well as generalized myasthenia gravis (gMG, approved in 2017) with positive anti-acetylcholine receptor (AchR) and neuromyelitis optica spectrum disorder with positive anti-aquaporin-4 (AQP4) (NMOSD, approved in 2019) (Patriquin and Kuo, 2019; Zhang et al., 2024).